DA
TNYA icon

Denali Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Denali Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,300
Closed -$226K – 438
2024
Q1 		$226K Hold
43,300
– – 0.07% 213
2023
Q4 		$140K Sell
43,300
-7,800
-15% -$16.8K 0.04% 255
2023
Q3 		$130K Hold
51,100
– – 0.05% 256
2023
Q2 		$300K Buy
+51,100
New +$297K 0.11% 189

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Denali Advisors's TNYA Position: Q2 2024 in Review

Denali Advisors sold out of Tenaya Therapeutics (TNYA) in Q2 2024, closing a stake of 43,300 shares — an estimated $226K sold.

Denali Advisors first reported a position in TNYA in Q2 2023 and held it in 4 quarters. The position peaked at $300K in Q2 2023. 96 funds tracked by Wall St. Rank hold TNYA as of Q2 2024.

  • Denali Advisors reported no remaining Tenaya Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 43,300 Tenaya Therapeutics shares in Q2 2024, an estimated $226K.
  • Denali Advisors first reported a position in Tenaya Therapeutics in Q2 2023 and held it in 4 quarters.
  • Denali Advisors's Tenaya Therapeutics position peaked at $300K in Q2 2023.
  • 96 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.